Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Olafsdottir, EJ, Borg, A, Jensen, M-B, Gerdes, A-M, Johansson, ALV, Barkardottir, RB, Johannsson, OT, Ejlertsen, B, Sønderstrup, IMH, Hovig, E, Lænkholm, A-V, Hansen, TVO, Olafsdottir, GH, Rossing, M, Jonasson, JG, Sigurdsson, S, Loman, N, Nilsson, MP, Narod, SA & Tryggvadottir, L 2020, 'Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status', British Journal of Cancer, bind 123, nr. 11, s. 1608-1615. https://doi.org/10.1038/s41416-020-01056-4

APA

Olafsdottir, E. J., Borg, A., Jensen, M-B., Gerdes, A-M., Johansson, A. L. V., Barkardottir, R. B., Johannsson, O. T., Ejlertsen, B., Sønderstrup, I. M. H., Hovig, E., Lænkholm, A-V., Hansen, T. V. O., Olafsdottir, G. H., Rossing, M., Jonasson, J. G., Sigurdsson, S., Loman, N., Nilsson, M. P., Narod, S. A., & Tryggvadottir, L. (2020). Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status. British Journal of Cancer, 123(11), 1608-1615. https://doi.org/10.1038/s41416-020-01056-4

CBE

Olafsdottir EJ, Borg A, Jensen M-B, Gerdes A-M, Johansson ALV, Barkardottir RB, Johannsson OT, Ejlertsen B, Sønderstrup IMH, Hovig E, Lænkholm A-V, Hansen TVO, Olafsdottir GH, Rossing M, Jonasson JG, Sigurdsson S, Loman N, Nilsson MP, Narod SA, Tryggvadottir L. 2020. Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status. British Journal of Cancer. 123(11):1608-1615. https://doi.org/10.1038/s41416-020-01056-4

MLA

Vancouver

Author

Olafsdottir, Elinborg J ; Borg, Ake ; Jensen, Maj-Britt ; Gerdes, Anne-Marie ; Johansson, Anna L V ; Barkardottir, Rosa B ; Johannsson, Oskar T ; Ejlertsen, Bent ; Sønderstrup, Ida Marie Heeholm ; Hovig, Eivind ; Lænkholm, Anne-Vibeke ; Hansen, Thomas van Overeem ; Olafsdottir, Gudridur H ; Rossing, Maria ; Jonasson, Jon G ; Sigurdsson, Stefan ; Loman, Niklas ; Nilsson, Martin P ; Narod, Steven A ; Tryggvadottir, Laufey. / Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status. I: British Journal of Cancer. 2020 ; Bind 123, Nr. 11. s. 1608-1615.

Bibtex

@article{0c290b0b2b7445708fd6b4a0563094df,
title = "Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status",
abstract = "BACKGROUND: The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of BRCA2 carriers.METHODS: We studied 608 women with invasive breast cancer and a pathogenic BRCA2 mutation (variant) from four Nordic countries. Information on prognostic factors and treatment was retrieved from health records and by analysis of archived tissue specimens. Hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression.RESULTS: About 77% of cancers were ER-positive, with the highest proportion (83%) in patients under 40 years. ER-positive breast cancers were more likely to be node-positive (59%) than ER-negative cancers (34%) (P < 0.001). The survival analysis included 584 patients. Positive ER status was protective in the first 5 years from diagnosis (multivariate HR = 0.49; 95% CI 0.26-0.93, P = 0.03); thereafter, the effect was adverse (HR = 1.91; 95% CI 1.07-3.39, P = 0.03). The adverse effect of positive ER status was limited to women who did not undergo endocrine treatment (HR = 2.36; 95% CI 1.26-4.44, P = 0.01) and patients with intact ovaries (HR = 1.99; 95% CI 1.11-3.59, P = 0.02).CONCLUSIONS: The adverse effect of a positive ER status in BRCA2 carriers with breast cancer may be contingent on exposure to ovarian hormones.",
author = "Olafsdottir, {Elinborg J} and Ake Borg and Maj-Britt Jensen and Anne-Marie Gerdes and Johansson, {Anna L V} and Barkardottir, {Rosa B} and Johannsson, {Oskar T} and Bent Ejlertsen and S{\o}nderstrup, {Ida Marie Heeholm} and Eivind Hovig and Anne-Vibeke L{\ae}nkholm and Hansen, {Thomas van Overeem} and Olafsdottir, {Gudridur H} and Maria Rossing and Jonasson, {Jon G} and Stefan Sigurdsson and Niklas Loman and Nilsson, {Martin P} and Narod, {Steven A} and Laufey Tryggvadottir",
year = "2020",
month = nov,
doi = "10.1038/s41416-020-01056-4",
language = "English",
volume = "123",
pages = "1608--1615",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "11",

}

RIS

TY - JOUR

T1 - Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status

AU - Olafsdottir, Elinborg J

AU - Borg, Ake

AU - Jensen, Maj-Britt

AU - Gerdes, Anne-Marie

AU - Johansson, Anna L V

AU - Barkardottir, Rosa B

AU - Johannsson, Oskar T

AU - Ejlertsen, Bent

AU - Sønderstrup, Ida Marie Heeholm

AU - Hovig, Eivind

AU - Lænkholm, Anne-Vibeke

AU - Hansen, Thomas van Overeem

AU - Olafsdottir, Gudridur H

AU - Rossing, Maria

AU - Jonasson, Jon G

AU - Sigurdsson, Stefan

AU - Loman, Niklas

AU - Nilsson, Martin P

AU - Narod, Steven A

AU - Tryggvadottir, Laufey

PY - 2020/11

Y1 - 2020/11

N2 - BACKGROUND: The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of BRCA2 carriers.METHODS: We studied 608 women with invasive breast cancer and a pathogenic BRCA2 mutation (variant) from four Nordic countries. Information on prognostic factors and treatment was retrieved from health records and by analysis of archived tissue specimens. Hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression.RESULTS: About 77% of cancers were ER-positive, with the highest proportion (83%) in patients under 40 years. ER-positive breast cancers were more likely to be node-positive (59%) than ER-negative cancers (34%) (P < 0.001). The survival analysis included 584 patients. Positive ER status was protective in the first 5 years from diagnosis (multivariate HR = 0.49; 95% CI 0.26-0.93, P = 0.03); thereafter, the effect was adverse (HR = 1.91; 95% CI 1.07-3.39, P = 0.03). The adverse effect of positive ER status was limited to women who did not undergo endocrine treatment (HR = 2.36; 95% CI 1.26-4.44, P = 0.01) and patients with intact ovaries (HR = 1.99; 95% CI 1.11-3.59, P = 0.02).CONCLUSIONS: The adverse effect of a positive ER status in BRCA2 carriers with breast cancer may be contingent on exposure to ovarian hormones.

AB - BACKGROUND: The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of BRCA2 carriers.METHODS: We studied 608 women with invasive breast cancer and a pathogenic BRCA2 mutation (variant) from four Nordic countries. Information on prognostic factors and treatment was retrieved from health records and by analysis of archived tissue specimens. Hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression.RESULTS: About 77% of cancers were ER-positive, with the highest proportion (83%) in patients under 40 years. ER-positive breast cancers were more likely to be node-positive (59%) than ER-negative cancers (34%) (P < 0.001). The survival analysis included 584 patients. Positive ER status was protective in the first 5 years from diagnosis (multivariate HR = 0.49; 95% CI 0.26-0.93, P = 0.03); thereafter, the effect was adverse (HR = 1.91; 95% CI 1.07-3.39, P = 0.03). The adverse effect of positive ER status was limited to women who did not undergo endocrine treatment (HR = 2.36; 95% CI 1.26-4.44, P = 0.01) and patients with intact ovaries (HR = 1.99; 95% CI 1.11-3.59, P = 0.02).CONCLUSIONS: The adverse effect of a positive ER status in BRCA2 carriers with breast cancer may be contingent on exposure to ovarian hormones.

UR - http://www.scopus.com/inward/record.url?scp=85091156088&partnerID=8YFLogxK

U2 - 10.1038/s41416-020-01056-4

DO - 10.1038/s41416-020-01056-4

M3 - Journal article

C2 - 32939053

VL - 123

SP - 1608

EP - 1615

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 11

ER -

ID: 61368879